TY - JOUR
T1 - Symptomatic acute myocarditis in 7 adolescents after pfizer-biontech covid-19 vaccination
AU - Marshall, Mayme
AU - Ferguson, Ian D.
AU - Lewis, Paul
AU - Jaggi, Preeti
AU - Gagliardo, Christina
AU - Collins, James Stewart
AU - Shaughnessy, Robin
AU - Caron, Rachel
AU - Fuss, Cristina
AU - Corbin, Kathleen Jo E.
AU - Emuren, Leonard
AU - Faherty, Erin
AU - Hall, E. Kevin
AU - Di Pentima, Cecilia
AU - Oster, Matthew E.
AU - Paintsil, Elijah
AU - Siddiqui, Saira
AU - Timchak, Donna M.
AU - Guzman-Cottrill, Judith A.
N1 - Publisher Copyright:
Copyright © 2021 by the American Academy of Pediatrics
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Trials of coronavirus disease 2019 (COVID-19) vaccination included limited numbers of children, so they may not have detected rare but important adverse events in this population. We report 7 cases of acute myocarditis or myopericarditis in healthy male adolescents who presented with chest pain all within 4 days after the second dose of Pfizer-BioNTech COVID-19 vaccination. Five patients had fever around the time of presentation. Acute COVID-19 was ruled out in all 7 cases on the basis of negative severe acute respiratory syndrome coronavirus 2 real-time reverse transcription polymerase chain reaction test results of specimens obtained by using nasopharyngeal swabs. None of the patients met criteria for multisystem inflammatory syndrome in children. Six of the 7 patients had negative severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody assay results, suggesting no previous infection. All patients had an elevated troponin. Cardiac MRI revealed late gadolinium enhancement characteristic of myocarditis. All 7 patients resolved their symptoms rapidly. Three patients were treated with nonsteroidal antiinflammatory drugs only, and 4 received intravenous immunoglobulin and corticosteroids. In this report, we provide a summary of each adolescent’s clinical course and evaluation. No causal relationship between vaccine administration and myocarditis has been established. Continued monitoring and reporting to the US Food and Drug Administration Vaccine Adverse Event Reporting System is strongly recommended.
AB - Trials of coronavirus disease 2019 (COVID-19) vaccination included limited numbers of children, so they may not have detected rare but important adverse events in this population. We report 7 cases of acute myocarditis or myopericarditis in healthy male adolescents who presented with chest pain all within 4 days after the second dose of Pfizer-BioNTech COVID-19 vaccination. Five patients had fever around the time of presentation. Acute COVID-19 was ruled out in all 7 cases on the basis of negative severe acute respiratory syndrome coronavirus 2 real-time reverse transcription polymerase chain reaction test results of specimens obtained by using nasopharyngeal swabs. None of the patients met criteria for multisystem inflammatory syndrome in children. Six of the 7 patients had negative severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody assay results, suggesting no previous infection. All patients had an elevated troponin. Cardiac MRI revealed late gadolinium enhancement characteristic of myocarditis. All 7 patients resolved their symptoms rapidly. Three patients were treated with nonsteroidal antiinflammatory drugs only, and 4 received intravenous immunoglobulin and corticosteroids. In this report, we provide a summary of each adolescent’s clinical course and evaluation. No causal relationship between vaccine administration and myocarditis has been established. Continued monitoring and reporting to the US Food and Drug Administration Vaccine Adverse Event Reporting System is strongly recommended.
UR - http://www.scopus.com/inward/record.url?scp=85108897074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108897074&partnerID=8YFLogxK
U2 - 10.1542/peds.2021-052478
DO - 10.1542/peds.2021-052478
M3 - Article
C2 - 34088762
AN - SCOPUS:85108897074
SN - 0031-4005
VL - 148
JO - Pediatrics
JF - Pediatrics
IS - 3
M1 - e2021052478
ER -